Ion Peptide

What Ion Peptide actually is

Ion Peptide is a US-based research-peptide vendor operating from a WordPress + WooCommerce storefront with a parallel wholesale-portal flow for distributors and clinics. The site presents as a relatively new entry to the audited cohort - the Wayback Machine first-archive date is mid-2025 and the Kovera testing pattern starts March 2026.

The catalog is structured around two parallel naming conventions. Most healing, longevity, and growth-factor peptides ship under their standard chemical names (BPC-157, GHK-Cu, CJC-1295/Ipamorelin, Tesamorelin, Sermorelin, PT-141). A subset of products ship under the coded ION-X naming convention (ION-1S, ION-2T, ION-3R) plus symbol-prefixed names (§-31, KSPTN). This is the obfuscation pattern we documented in our code-name catalogs article - a hedge against FDA enforcement letters that ask "are you selling compound X" rather than "what is in your ION-X SKU."

The COA practice is where Ion Peptide stands out.

Why Ion Peptide leads on COA volume

Across the 120 records in our Kovera Labs mirror (March 22 to May 23, 2026), Ion Peptide carries:

That's the cleanest two-month batch in our entire Kovera-tested vendor pool. For context, the next closest heavy publisher (Glacier Aminos at 77 records) carries 3 identity-mismatch flags, and the third (Instant Peptides at 72 records) carries 5 purity failures plus 3 identity-mismatch flags. Ion Peptide simply has no flagged records in the period.

The records cover the meaningful diversity of their catalog: BPC-157, BPC-157/TB-500 blends, CJC-1295/Ipamorelin, GHK-Cu/KPV blends, PT-141, Tesamorelin, Sermorelin, AOD-9604, Glutathione, Thymosin alpha-1, plus the coded ION-X line and the symbol-prefixed §-31 and KSPTN entries.

We covered the broader Kovera corpus methodology in our 1,816-COA analysis - same independent lab, same per-record verifier URL pattern, same publication discipline (failures appear alongside passes in Kovera's public listing, which is the structural property that makes the corpus a credible signal in the first place).

The coded-SKU caveat

The audit credits Ion Peptide heavily for the COA pattern, but the coded ION-X line deserves explicit framing because it cuts in two directions.

The argument for: in a regulatory environment where FDA enforcement letters often cite "Vendor X is selling compound Y," a vendor using ION-3R as a SKU has a defensible "we sold ION-3R, you'll have to subpoena us to learn what's in it" posture. That's the same defensive posture we documented across multiple alias-cluster vendors in our 32-vendor alias scan.

The argument against: a buyer comparing Ion Peptide to a vendor using clear chemical names cannot do a like-for-like comparison at the cart. The Kovera COA for an ION-3R vial will identify the compound (the lab can run mass spec independent of what the vendor calls it), but the buyer has to read that COA carefully before they know what they are actually buying. For a research-protocol audience that knows the field, this may be acceptable. For a less-expert buyer, it's a friction.

We are not deducting on this dimension at the audit-tier level because the COA disclosure pattern still wins. But it's a real consideration buyers should hold.

Shipping, support, payments

Shipping: Same-day fulfillment on orders placed before 6pm EST Monday-Friday or 3pm Saturday. Carriers are FedEx 2-Day Express or UPS Ground. The same-day cutoff with named carriers is a transparency signal most vendors in the niche don't publish explicitly.

Support: Live chat staffed 9am-1am EST daily (16-hour coverage, no weekends-off gap). Email channel via the contact page.

Payments: Card via the WooCommerce default, plus crypto handling typical for the category. We could not confirm wire / ACH availability from the public site.

Wholesale portal: Some catalog tiers require account registration. The registration flow asks for business type (Researcher / Clinic / University / Distributor / Other) and date-of-birth verification. This is mainstream for the category.

What's missing from public records

This audit is public-data tier. To upgrade Ion Peptide to a full audit tier we would need:

• A first-hand vialaudit order placed at retail, shipped to a private mailbox, with the vial then sent to Janoshik for independent retesting
• Cross-check of an ION-X coded SKU against the COA-stated compound, to confirm what the coded SKUs actually contain
• Per-batch consistency check across 6-12 months of testing, not just the two-month March-May 2026 Kovera window
• Verification of state-by-state shipping policy and any blocked-state restrictions
• Confirmation of payment-method coverage beyond what the public catalog displays
• The named operator behind the brand, cross-checked against state business-registration records

We have not done that work yet. This profile reflects what is verifiable from public records as of the last-tested date.

Editorial note - the COA-pattern leader, with a caveat

Ion Peptide currently holds the highest COA-volume rank in our audited cohort. 120 published Kovera COAs at 99.927% median purity with zero flags is the cleanest two-month publishing record we have measured. The audit weights this heavily.

The coded ION-X SKU pattern is the only meaningful caveat. It is not disqualifying - the COA disclosure compensates - but buyers should treat ION-3R or §-31 in the cart the same way they would treat any unfamiliar SKU: read the COA before buying.

See our methodology for the rubric weights that produce this score and the conflict-of-interest constraints that govern this desk.

• Ion Peptide homepage↗ — vendor
• Ion Peptide public COA / lab-results page↗ — vendor
• Ion Peptide about page↗ — vendor
• Ion Peptide RUO policy↗ — vendor
• Kovera Labs public verifier (120 Ion Peptide records, May 2026)↗ — third-party-lab
• vialaudit - 1,816 Kovera Labs COAs analysis — vialaudit
• vialaudit - Code-name catalogs: FDA evasion analysis — vialaudit